Yan Xie, PhD, of the VA Saint Louis Health Care System, and colleagues conducted a longitudinal observational cohort study using administrative data from the U.S. Department of Veterans Affairs. Researchers followed 349,312 new users of PPIs or histamine H2 receptor antagonists for a median of 5.71 years.
Additional subject groups included PPI users versus no PPI users (3.2 million subjects) and PPI users versus no PPI and no H2 blocker users (2.8 million subjects).
Here’s what they found:
1. PPI use increased risk of patient death compared to patients only on H2 blockers.
2. PPI users had a higher death risk in analyses adjusted for “high-dimensional propensity scores in two-stage residual inclusion estimation and in one-of-one time-dependent propensity-score matched cohorts.”
3. PPI users without gastrointestinal diseases had a higher death risk, as well.
4. Researchers established a graded association between exposure duration and risk of death.
Researchers concluded, “The results suggest excess risk of death among PPI users; risk is also increased among those without gastrointestinal conditions and with prolonged duration of use. Limiting PPI use and duration to instances where it is medically indicated may be warranted.”
The American Gastroenterological Association released a conversation guide for providers on the new study.
The organization said providers should reassure patients that while the research could be frightening, the study, “still indicates that those who have a diagnosed condition that is helped by PPIs should stay on them, as benefits can outweigh those risks.”
More articles on gastroenterology:
Effector, Pfizer, Merck partner to test novel immuno-oncology agents in CRC — 4 key notes
GI center to know: Gastroenterology Consultants of Southwest Virginia
Sucampo Pharmaceuticals aims to grow Amitiza line — 4 key notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.